Prognostic factors in patients with pancreatic cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 3, 2012, Pages 423-432

  Zhang, De Xiang ^a   Dai, Yue Di ^b   Yuan, Su Xu ^c   Tao, Li ^b  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Clinicopathological parameters; Pancreatic cancer; Prognostic factor; Treatment selection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BILIARY TRACT DRAINAGE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERVIEW; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

EID: 84862968600     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.412     Document Type: Article

References (23)

1. Goldstein D, Carroll S, Apte M, et al: Modern management of pancreatic carcinoma. Intern Med J 34: 475-481, 2004.
2. Hirata K, Sato T, Mukaiya M, et al: Results of 1001 resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 132: 771-776, 1997.
3. Nakao A, Harada A, Nonami T, et al: Lymph node metastasis in carcinoma of the body and tail of the pancreas. Br J Surg 84: 1090-1092, 1997.
4. Shimada K, Sakamoto Y, Sano T, et al: Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 139: 288-295, 2006.
5. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210, 2004.
6. Zhang QH and Li QX: Clinical analysis of 2340 cases of pancreatic carcinoma. Natl Med J China 84: 214-218, 2004.
7. Kanda M, Fujii T, Kodera Y, et al: Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98: 268-274, 2011.
8. Murakami Y, Uemura K, Sudo T, et al: Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 211: 196-204, 2010.
9. Boggi U, del Chiaro M, Croce C, et al: Prognostic implications of tumor invasion of adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 146: 869-881, 2009.
10. Fatima J, Schnelldorfer T, Barton J, et al: Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 145: 167-172, 2010.
11. Heinemann V: Present and future treatment of pancreatic carcinoma. Semin Oncol 29: 23-31, 2002.
12. Chua YJ and Cunningham D: Adjuvant treatment for respectable pancreatic cancer. J Clin Oncol 23: 4532-4537, 2005.
13. Li D, Xie K, Wolff R, et al: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
14. Joo KP, Yong BY, Yong-Tae K, et al: Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 42: 86-91, 2008.
15. Heinemann V: Gemcitabine in the treatment of advanced pancreatic carcinoma: a comparative analysis of randomized trials. Semin Oncol 29: 9-16, 2002.
16. Emilio B, Michele M, Alain G, et al: Gemcitabine-based combinations for inoperable pancreatic carcinoma: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 110: 525-533, 2007.
17. Heinemann V, Labianca R, Hinke A, et al: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18: 1652-1659, 2007.
18. Burris HA III, Moore MJ, Green MR, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
19. Takeo F, Toshio N, Naoto G, et al: Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas 39: 48-54, 2010.
20. Ichiro W, Satoshi S, Masaru K, et al: Onset symptoms and tumor locations as prognostic factors of pancreatic carcinoma. Pancreas 28: 160-165, 2004.
21. Faruk T, Faruk A, Suleyman A, et al: Prognostic factors in pancreatic carcinoma serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24: 547-550, 2001.
22. Louhimo J, Alfthan H, Stenman UH, et al: Serum HCG beta and CA72-4 are stronger prognostic factors than CEA, CA19-9 and CA242 in pancreatic cancer. Oncology 66: 126-131, 2004.
23. Kim JE, Lee KT, Lee JK, et al: Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19: 182-186, 2004.